Brief: Ergomed and Boryung Pharmaceutical Co enter agreement to commercialise Ergomed's haemostat products in South Korea
27/09/2017 07:06
Sept 27 (Reuters) - ERGOMED ERGO.L :
* SAYS CO AND BORYUNG PHARMACEUTICAL CO ANNOUNCE AGREEMENT
TO COMMERCIALISE ERGOMED'S HAEMOSTAT PRODUCTS PEPROSTAT AND
READYFLOW IN SOUTH KOREA
Source text for Eikon: ID:nRSa8982Ra
Further company coverage: ERGO.L
(Bangalore.newsroom@thomsonreuters.com)
Recent news on Boryung
See all newsBrief: Boryung Corp Q1 Operating Profit 20.2 Billion Won, Up 84.7% From Year Earlier
Brief: Boryung Corp Q4 Operating Profit 20 Billion Won, Up 36% From Year Earlier
Brief: Boryung Corp Q2 Operating Profit 25.4 Billion Won, Up 26% From Year Earlier
Brief: Boryung Q1 Operating Profit 11 Billion Won, Down 33% From Year Earlier
Brief: Boryung Corp Q4 Operating Profit 14.6 Billion Won, Down 1.5% From Year Earlier